AR011860A1 - Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas - Google Patents

Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas

Info

Publication number
AR011860A1
AR011860A1 ARP980100810A ARP980100810A AR011860A1 AR 011860 A1 AR011860 A1 AR 011860A1 AR P980100810 A ARP980100810 A AR P980100810A AR P980100810 A ARP980100810 A AR P980100810A AR 011860 A1 AR011860 A1 AR 011860A1
Authority
AR
Argentina
Prior art keywords
preparation
neurodegenerative diseases
dementia
application
procedure
Prior art date
Application number
ARP980100810A
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of AR011860A1 publication Critical patent/AR011860A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Preparado de combinacion para la aplicacion en la demencia, que contiene al menos: 1) un compuesto que presenta un efecto inhibidor de laacetilcolinesterasa o muestra un efecto muscarinogeno; 2) un compuesto que aumenta el nivel de adenosinaextracelular endogeno; 3) un soportefarmacéutico, con un aumento supraaditivo del efecto muscarínico en el caso de enfermedades neurodegenerativas, para la aplicacion simultánea, separadao escalonada en el tiempo. Además la invencion describe unprocedimiento para la produccion del preparado y el empleo del mismo para la preparacion de unmedicamento util para el tratamiento de enfermedades neurodegenerativas, en particular la demencia senil.
ARP980100810A 1997-02-26 1998-02-24 Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas AR011860A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19707655A DE19707655A1 (de) 1997-02-26 1997-02-26 Kombinationspräparat zur Anwendung bei Demenz

Publications (1)

Publication Number Publication Date
AR011860A1 true AR011860A1 (es) 2000-09-13

Family

ID=7821517

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100810A AR011860A1 (es) 1997-02-26 1998-02-24 Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas

Country Status (30)

Country Link
US (1) US6037347A (es)
EP (1) EP0867192B1 (es)
JP (1) JP4374440B2 (es)
KR (1) KR100517186B1 (es)
CN (1) CN100363005C (es)
AR (1) AR011860A1 (es)
AT (1) ATE295738T1 (es)
AU (1) AU749278C (es)
BR (1) BR9800766A (es)
CA (1) CA2230350C (es)
CZ (1) CZ298367B6 (es)
DE (2) DE19707655A1 (es)
DK (1) DK0867192T3 (es)
EE (1) EE03387B1 (es)
ES (1) ES2242243T3 (es)
HR (1) HRP980097B1 (es)
HU (1) HUP9800396A3 (es)
ID (1) ID19941A (es)
IL (1) IL123453A (es)
MY (1) MY120530A (es)
NO (1) NO327200B1 (es)
NZ (1) NZ329839A (es)
PL (1) PL191576B1 (es)
PT (1) PT867192E (es)
RU (1) RU2194508C2 (es)
SI (1) SI0867192T1 (es)
SK (1) SK284925B6 (es)
TR (1) TR199800302A2 (es)
TW (1) TW590772B (es)
ZA (1) ZA981561B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237163T3 (es) * 1998-10-01 2005-07-16 Novartis Ag Nuevas formulaciones orales de revastigmina de liberacion controlada.
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
WO2004028634A1 (en) * 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
RU2616247C1 (ru) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Твердая лекарственная форма, обладающая холинопозитивным действием, на основе 9-бутиламино-3,3-диметил-1,2,4-тригидроакридина

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
IL87861A0 (en) * 1987-10-05 1989-03-31 Pfizer 4-aminopyridine derivatives
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
JPH05506842A (ja) * 1989-09-15 1993-10-07 ジェンシア・ファーマシュウティカルズ・インコーポレイテッド 神経変性状態の処置方法
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment

Also Published As

Publication number Publication date
HRP980097B1 (en) 2006-09-30
ATE295738T1 (de) 2005-06-15
CA2230350A1 (en) 1998-08-26
AU5627398A (en) 1998-09-03
KR19980071717A (ko) 1998-10-26
KR100517186B1 (ko) 2005-12-05
HUP9800396A3 (en) 2001-05-28
NO980786L (no) 1998-08-27
TR199800302A3 (tr) 1998-09-21
PL325074A1 (en) 1998-08-31
NO980786D0 (no) 1998-02-25
EP0867192A3 (de) 2000-12-06
MY120530A (en) 2005-11-30
IL123453A (en) 2004-06-20
CN1192904A (zh) 1998-09-16
EP0867192A2 (de) 1998-09-30
HU9800396D0 (en) 1998-04-28
ID19941A (id) 1998-08-27
TR199800302A2 (xx) 1998-09-21
DK0867192T3 (da) 2005-09-05
RU2194508C2 (ru) 2002-12-20
EE9800075A (et) 1998-10-15
CA2230350C (en) 2007-07-24
PL191576B1 (pl) 2006-06-30
SI0867192T1 (en) 2005-10-31
SK24098A3 (en) 1998-09-09
DE19707655A1 (de) 1998-08-27
HUP9800396A1 (hu) 1999-07-28
CN100363005C (zh) 2008-01-23
EP0867192B1 (de) 2005-05-18
HRP980097A2 (en) 1998-12-31
DE59812801D1 (de) 2005-06-23
NO327200B1 (no) 2009-05-11
JP4374440B2 (ja) 2009-12-02
BR9800766A (pt) 1999-12-07
MX9801515A (es) 1998-08-30
AU749278C (en) 2003-07-31
EE03387B1 (et) 2001-04-16
AU749278B2 (en) 2002-06-20
PT867192E (pt) 2005-08-31
SK284925B6 (sk) 2006-02-02
CZ54098A3 (cs) 1998-09-16
TW590772B (en) 2004-06-11
US6037347A (en) 2000-03-14
JPH10236979A (ja) 1998-09-08
ZA981561B (en) 1998-08-26
NZ329839A (en) 2000-05-26
CZ298367B6 (cs) 2007-09-12
ES2242243T3 (es) 2005-11-01
IL123453A0 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
EP1449834A3 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
CR6593A (es) Composicion constituida de material tramadol y una droga anticonvulsionante
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
DE69429527T2 (de) Inhibitoren von beta-amyloid-protein-herstellung
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
DE69820108D1 (de) Doppelkapsel zur verabreichung von arzneimitteln für vielfache therapien
EP1140840A4 (en) DIPHENYLUREA WITH SUBSTITUENTS -G (V) -CARBOXYARYLES, INHIBITORS OF RAF KINASE
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
BR0213355A (pt) composições farmacêuticas
AR011860A1 (es) Preparado de combinacion para la aplicacion en la demencia, un procedimiento para su produccion y el empleo del mismo para la preparacionde un medicamento util para el tratamiento de enfermedades neurodegenerativas
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
MX9207008A (es) Medicamentos para el tratamiento de condiciones inflamatorias o para la analgesia.
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
ECSP003707A (es) Diazepanes
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
SE9802937D0 (sv) Novel compounds
DE9217555U1 (de) Behältnis zur einzelportionierten Ausgabe von Tabletten o.dgl.
NO20021625L (no) Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
FI942400A0 (fi) Lääkeaine hermosairauksia vastaan
MX9202507A (es) Composicion farmaceutica para el tratamiento de esofagitis de reflujo.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.

Legal Events

Date Code Title Description
FC Refusal